Company: NGVT
Filing Date: 2025-02-19
Form Type: 10-K
Source: 0001653477-25-000015
Chunk: 1105

Company: Ingevity Corp
Filing Date: 2025-02-19
Form: 10-K
Item: Item 8
Chunk 1105
---
 Units(in thousands) (1)Weighted average grant date fair value (per share)Number of Units(in thousands) (1)Weighted average grant date fair value (per share)Nonvested, December 31, 2023350 $72.06 263 $72.02 Granted179 42.48 127 45.22 Vested(145)74.55 (35)69.65 Forfeited(76)60.38 (142)58.58 Nonvested, December 31, 2024 (2)308 $56.52 213 $65.44 _______________(1) The number granted represents the number of shares issuable upon vesting of RSUs and DSUs. For PSUs, the number granted represents the number of shares issuable upon vesting, assuming that Ingevity performs at the target performance level in each year of the three-year performance period.(2) Excludes 19,068 non-employee director shares that were vested but unissued at December 31, 2024.As of December 31, 2024, $11.6 million of unrecognized share-based compensation expense related to RSUs, DSUs and PSUs is expected to be recognized over a weighted-average period of 1 year.

80

IndexIngevity CorporationNotes to the Consolidated Financial StatementsDecember 31, 2024

Note 12: Equity

Accumulated other comprehensive income (loss)Summarized below is the roll forward of AOCI, net of tax.Years Ended December 31,In millions202420232022Foreign currency translationBeginning balance$(25.6)$(45.8)$18.4 Net gains (losses) on foreign currency translation(18.6)20.2 (74.9)Reclassification of foreign currency translation losses(0.2)— — Gains (losses) on net investment hedges— — 13.9 Less: tax provision (benefit)— — 3.2 Net gains (losses) on net investment hedges— — 10.7 Other comprehensive income (loss), net of tax(18.8)20.2 (64.2)Ending balance$(44.4)$(25.6)$(45.8)Derivative instrumentsBeginning balance$(1.6)$(1.4)$(2.1